论文部分内容阅读
目的探讨高能聚焦超声治疗(HIFU)对胰腺癌患者血清癌胚抗原(CEA)、糖类抗原199(CA199)的影响。方法采外周血用电化学发光法测定31例HIFU治疗前、后胰腺癌患者和30例健康人血清中CEA、CA199的含量。结果治疗前胰腺癌患者血清CEA、CA199含量[分别为(50．65±43．11)ng／ml,(126．08±77．21) U／ml]较健康人[(4．44±5．34)ng／ml,(37．32±19．39)U／ml]明显升高,差异有统计学意义(P<0．001)。治疗后胰腺癌患者血清CEA、CA199含量[(18．91±33．00)ng／ml,(52．92±55．61)U／ml]较治疗前明显下降,差异有统计学意义(P<0．01),其中CEA较健康人比较差异有统计学意义(P<0．05);CA199接近健康人,差异无统计学意义(P>0．05)。治疗后完全缓解及部分缓解胰腺癌患者血清中CEA和CA199的含量[(4．14±3．29)ng／ml,(23．43±18．23)U／ml]明显低于稳定及进步的胰腺癌患者[(28．24±39．63)ng／ml,(71．55±63．28)U／ml],差异有统计学意义(P<0．05),生存期≥1年的胰腺癌患者血清中CEA和CA199的含量[(6．11±7．49)ng／ml,(32．66±25．06)U／ml]明显低于生存期<1年的患者[(32．57±43．42)ng／ml,(74．54±70．60)U／ml],差异有统计学意义(P <0．05)。结论血清CEA和CA199可作为胰腺癌诊断、疗效观察和预后判断的辅助指标,HIFU能明显下调胰腺癌血清CEA和CA199水平。
Objective To investigate the effect of high-energy focused ultrasound (HIFU) on serum carcinoembryonic antigen (CEA) and carbohydrate antigen 199 (CA199) in patients with pancreatic cancer. Methods The serum levels of CEA and CA199 in 31 patients with pancreatic cancer before and after treatment with HIFU and 30 healthy subjects were determined by electrochemiluminescence. Results The serum levels of CEA and CA199 in patients with pancreatic cancer before treatment were [(50.65±43.11) ng/ml, (126.08±77.21) U/ml] compared with healthy individuals [(4.44±5). .34) ng/ml, (37.32±19.39) U/ml] was significantly higher and the difference was statistically significant (P<0.001). After treatment, serum CEA and CA199 levels in patients with pancreatic cancer [(18.91±33.00) ng/ml, (52.92±55.61) U/ml] were significantly lower than before treatment, and the difference was statistically significant (P <0.01), of which CEA was significantly different from healthy subjects (P<0.05); CA199 was close to healthy subjects, the difference was not statistically significant (P>0.05). The serum levels of CEA and CA199 in patients with complete or partial remission of pancreatic cancer after treatment (4.14±3.29 ng/ml, (23.43±18.23) U/ml) were significantly lower than the stability and progress Patients with pancreatic cancer [(28.24±39.63) ng/ml, (71.55±63.28) U/ml], the difference was statistically significant (P<0.05), and the survival period was ≥1 year The serum levels of CEA and CA199 in patients with pancreatic cancer [(6.11±7.49) ng/ml, (32.66±25.06) U/ml] were significantly lower than those in patients whose survival period was <1 year [( 32.57 ± 43.42) ng / ml, (74.54 ± 70.60) U / ml], the difference was statistically significant (P <0.05). Conclusion Serum CEA and CA199 can be used as auxiliary markers for diagnosis, curative effect observation and prognosis judgment of pancreatic cancer. HIFU can significantly down-regulate serum CEA and CA199 levels of pancreatic cancer.